新宫颈癌肿瘤标志物P16自身抗体的表达

发布时间：2018-10-31 08:51

【摘要】：目的研究早期宫颈恶性肿瘤、宫颈良性肿瘤和健康人群P16自身抗体表达情况。方法利用自行设计的P16表位多肽片段作为包被抗原,采用改良Eli SA方法检测141例宫颈癌患者、133例宫颈良性肿瘤患者和148例健康志愿者血浆中P16自身抗体的表达情况。结果恶性肿瘤组P16自身抗体表达水平显著高于健康对照组(t=4.016,P0.001)和良性肿瘤组(t=3.879,P0.001)。Ⅰ期宫颈癌组和Ⅱ期宫颈癌组P16表达水平明显高于健康人群(t=7.800,P0.001;t=5.198,P0.001)及良性肿瘤组(t=4.466,P0.001;t=2.288,P0.001),且Ⅰ期宫颈癌组与Ⅱ期宫颈癌组P16自身抗体表达水平存在差异(t=2.012,P0.05)。宫颈癌组特异度为90%时,敏感度15.6%,曲线下面积为0.652。Ⅰ期宫颈癌组抗P16的Ig G自身抗体特异度为90%时,敏感度达到了20.3%,曲线下面积为0.719。结论 P16作为一种肿瘤相关抗原,其自身抗体可以反映出宫颈病变的连续发展变化,可能是早期诊断宫颈病变的一种潜在血清学标志物。
[Abstract]:Objective to study the expression of P16 autoantibodies in early cervical malignancies, benign cervical neoplasms and healthy people. Methods the expression of P16 autoantibodies in plasma of 141 patients with cervical cancer, 133 patients with benign cervical tumor and 148 healthy volunteers was detected by modified Eli SA method. Results the expression level of P16 autoantibody in malignant tumor group was significantly higher than that in healthy control group (t = 4.016) and benign tumor group (t = 3.879). P0.001. The expression of P16 in patients with stage 鈪，

本文编号：2301575